Affinage

TNFAIP2

Tumor necrosis factor alpha-induced protein 2 · UniProt Q03169

Length
654 aa
Mass
72.7 kDa
Annotated
2026-04-28
40 papers in source corpus 20 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TNFAIP2 is a TNF-α- and NF-κB-inducible cytosolic protein that orchestrates actin remodeling, cell migration, membrane receptor trafficking, and intercellular communication by activating the small GTPases Rac1 and Cdc42. It directly binds Rac1/Cdc42 (partly through an Integrin β4–IQGAP1 scaffold) to drive actin-based protrusions, epithelial–mesenchymal transition, and tumor invasion, and signals through a Rac1→ERK→AP-1 axis to transcriptionally activate HIF1α and VEGF-dependent angiogenesis (PMID:26189798, PMID:37787041, PMID:39532855). TNFAIP2 also binds PIP2 and engages RalA and the exocyst complex to promote CSF1R clustering and surface trafficking in macrophages, mediates tunneling nanotube formation enabling intercellular organelle transfer in podocytes, and competes with NRF2 and IKKβ for KEAP1 binding via its DLG motif, thereby stabilizing both proteins and modulating oxidative-stress and NF-κB signaling (PMID:39939179, PMID:35659195, PMID:37525222, PMID:39948570). Its transcription is driven by NF-κB, STAT1–EP300, KLF5 (acetylated by TGF-β signaling), and PML-RARα/retinoic acid, while its translation is controlled by inhibitory upstream open reading frames that are relieved during monocyte-to-macrophage differentiation (PMID:23975427, PMID:34112215, PMID:40054652, PMID:31392347).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1994 Medium

    Identifying TNFAIP2 as a TNF-α primary response gene with tissue-restricted isoforms established a new TNF-inducible effector with potential roles in hematopoiesis and spermatogenesis.

    Evidence In situ hybridization, Northern blot, and immunostaining in mouse tissues

    PMID:8106408

    Open questions at the time
    • No functional assay to link expression to a cellular process
    • Acrosomal function of truncated isoform unknown
  2. 2000 Medium

    Demonstrating that PML-RARα directly activates TNFAIP2 transcription upon retinoic acid treatment placed the gene within the differentiation program of acute promyelocytic leukemia cells.

    Evidence Microarray, RT-PCR, actinomycin D and cycloheximide inhibition in TF1-PR cells

    PMID:10766166

    Open questions at the time
    • No downstream effector pathway identified
    • Role of PML coiled-coil domain in transcriptional activation not mechanistically resolved
  3. 2013 High

    Mapping the NF-κB binding site on the TNFAIP2 promoter and showing TNFAIP2 co-immunoprecipitates with actin and promotes membrane protrusions resolved how NF-κB signaling connects to cytoskeletal remodeling and cell motility.

    Evidence Luciferase reporter, p65 siRNA, co-IP, immunofluorescence, transwell migration in NPC cells

    PMID:23975427

    Open questions at the time
    • Direct actin-binding domain not mapped
    • Whether TNFAIP2 nucleates or bundles actin filaments unknown
  4. 2015 High

    Identifying TNFAIP2 as a direct KLF5 target and showing it activates Rac1 and Cdc42 GTPases revealed the core molecular mechanism by which TNFAIP2 remodels the cytoskeleton and promotes invasion.

    Evidence ChIP, co-IP, Rac1/Cdc42 pull-down activity assays, siRNA rescue in breast cancer cells

    PMID:26189798

    Open questions at the time
    • Whether TNFAIP2 acts as a GEF, GEF scaffold, or GDI competitor not determined
    • Structural basis of Rac1/Cdc42 interaction unknown
  5. 2015 Medium

    Showing TNFAIP2 inhibits NF-κB activity and IL-8 production revealed a negative feedback loop in the TNFα response, with a clinical genetic correlate in septic shock.

    Evidence NF-κB reporter assay, IL-8 measurement, rs8126 genetic association

    PMID:26347487

    Open questions at the time
    • Mechanism of NF-κB inhibition not defined at this stage
    • Genetic association not replicated in independent cohort
  6. 2019 High

    Discovering that inhibitory upstream open reading frames suppress TNFAIP2 translation in monocytes and are relieved during macrophage differentiation established a post-transcriptional gate controlling TNFAIP2 protein levels.

    Evidence uORF mutagenesis reporter assays, polysome profiling, monocyte differentiation model

    PMID:31392347

    Open questions at the time
    • Trans-acting factors that inactivate the uORFs unidentified
    • Whether eIF2α phosphorylation or specific initiation factor changes mediate uORF bypass unknown
  7. 2020 High

    Genetic ablation of Tnfaip2 in embryonic stem cells revealed an unexpected requirement for TAG/lipid droplet synthesis and vimentin expression during differentiation, broadening the gene's role beyond cytoskeletal regulation to lipid metabolism.

    Evidence Tnfaip2 KO ESCs, lipidomic analysis, vimentin epistasis, palmitic acid rescue

    PMID:33300287

    Open questions at the time
    • Direct enzyme or transporter through which TNFAIP2 controls TAG synthesis unknown
    • Whether lipid effects are Rac1/Cdc42-dependent not tested
  8. 2021 Medium

    Showing that phospho-STAT1 recruits EP300 to deposit H3K27ac at TNFAIP2 enhancers added an interferon/inflammatory transcriptional axis to the gene's regulatory inputs.

    Evidence ChIP-PCR, STAT1–EP300 co-IP, EP300 inhibitor in DSS colitis mouse model

    PMID:34112215

    Open questions at the time
    • Whether STAT1-driven induction is independent of NF-κB co-activation not formally dissected
    • Enhancer–promoter contact not confirmed by 3C/4C
  9. 2022 High

    Demonstrating that TNFAIP2 drives tunneling nanotube formation enabling autophagosome and lysosome transfer between podocytes established a novel intercellular organelle exchange mechanism with in vivo relevance in diabetic nephropathy.

    Evidence Tnfaip2 KO mice with STZ-induced DN, live-cell imaging of organelle transfer, autophagic flux assays

    PMID:35659195

    Open questions at the time
    • Molecular mechanism connecting TNFAIP2 to TNT biogenesis not defined
    • Whether Rac1/Cdc42 activation is required for TNT formation not tested
  10. 2023 High

    Identifying a DLG motif in TNFAIP2 that directly binds the KEAP1 Kelch domain, displacing NRF2 from ubiquitination, provided a structural mechanism for TNFAIP2-mediated antioxidant defense and cisplatin resistance.

    Evidence Co-IP/MS, DLG motif mutagenesis, ROS measurement, xenograft and 4NQO mouse models

    PMID:37525222

    Open questions at the time
    • Binding affinity relative to NRF2 ETGE/DLG motifs not quantified
    • Crystal structure of TNFAIP2-KEAP1 complex unavailable
  11. 2023 High

    Revealing that Integrin β4 activates Rac1 through a TNFAIP2–IQGAP1 scaffolding complex explained how extracellular matrix signals converge on TNFAIP2-dependent GTPase signaling to confer drug resistance.

    Evidence Reciprocal co-IP, Rac1 activity assay, siRNA epistasis in triple-negative breast cancer cells

    PMID:37787041

    Open questions at the time
    • Stoichiometry and direct vs. indirect TNFAIP2–IQGAP1 interaction not resolved
    • Whether this complex is constitutive or signaling-induced not determined
  12. 2024 High

    Mapping a Rac1→ERK→AP-1 cascade downstream of TNFAIP2 that transcriptionally activates HIF1α connected cytoskeletal GTPase signaling to angiogenesis in triple-negative breast cancer.

    Evidence ChIP (AP-1 on HIF1α promoter), luciferase reporter, ERK/VEGFR inhibitors, xenograft model

    PMID:39532855

    Open questions at the time
    • Whether TNFAIP2-driven HIF1α induction operates under normoxia vs. hypoxia not fully dissected
    • Contribution of Cdc42 vs. Rac1 to this axis not separated
  13. 2025 High

    Demonstrating that TNFAIP2 binds PIP2 and engages RalA and the exocyst complex to cluster and traffic CSF1R to the macrophage surface established TNFAIP2 as a lipid-binding organizer of receptor signaling platforms.

    Evidence PIP2-binding motif mutagenesis, PIP2 depletion, CSF1R clustering reconstitution in 293 cells, RalA and exocyst co-IP

    PMID:39939179 PMID:41158107

    Open questions at the time
    • Whether PIP2 binding is required for all TNFAIP2 functions (e.g., TNT formation, GTPase activation) not tested
    • Structural basis of PIP2 recognition undefined
  14. 2025 Medium

    Showing that TNFAIP2 competes with IKKβ for KEAP1 binding to prevent K63-linked ubiquitination and degradation of IKKβ unified the KEAP1-competition mechanism with sustained NF-κB signaling.

    Evidence Co-IP, ubiquitination assay, conditional Tnfaip2 KO in 4NQO-induced OSCC mouse model

    PMID:39948570

    Open questions at the time
    • Whether KEAP1 binds IKKβ and NRF2 at the same site or distinct sites when TNFAIP2 is present not resolved
    • Relative contribution of NRF2 stabilization vs. IKKβ stabilization to tumor phenotypes not separated

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the precise biochemical activity of TNFAIP2 toward Rac1/Cdc42 (GEF, scaffold, or GDI-displacement factor), the structural basis of its interactions with KEAP1, PIP2, and GTPases, and how the diverse effector outputs (cytoskeletal remodeling, TNT formation, lipid metabolism, receptor clustering) are coordinated or context-selected.
  • No in vitro reconstitution of GEF or GEF-scaffold activity
  • No high-resolution structure of TNFAIP2 or its complexes
  • Context-specific regulation determining which effector pathway dominates is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0008092 cytoskeletal protein binding 2 GO:0060090 molecular adaptor activity 2 GO:0008289 lipid binding 1
Localization
GO:0005829 cytosol 3 GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-168256 Immune System 2 R-HSA-8953897 Cellular responses to stimuli 2 R-HSA-1266738 Developmental Biology 1 R-HSA-9612973 Autophagy 1
Partners
ACTINCDC42CSF1RIQGAP1ITGB4KEAP1RAC1RALA

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 B94/TNFAIP2 is a primary response gene induced by TNF-α in endothelial cells; the mouse homologue is expressed in hematopoietic tissues and the sperm acrosome, with a truncated testis-specific transcript arising from an alternate polyadenylation signal within the open reading frame. Immunostaining localized B94 protein to the acrosomal compartment of mature sperm. In situ hybridization, Northern blot, affinity-purified polyclonal antiserum immunostaining, mouse chromosomal mapping The Journal of biological chemistry Medium 8106408
2000 TNFAIP2 (B94) is a retinoic acid target gene in acute promyelocytic leukemia cells expressing PML-RARα; induction is rapid (within 1 h), does not require new protein synthesis, is blocked by actinomycin D, and is dependent on the PML coiled-coil domain of PML-RARα, indicating direct transcriptional activation. cDNA microarray, quantitative RT-PCR, actinomycin D and cycloheximide inhibition assays in TF1-PR cells Cancer research Medium 10766166
2010 Knockdown of TNFAIP2 by siRNA dramatically reduces migration and invasion of nasopharyngeal carcinoma HK1 cells, establishing a direct role for TNFAIP2 in promoting cell motility. siRNA knockdown, transwell migration and invasion assays Modern pathology Medium 21057457
2013 The EBV oncoprotein LMP1 transcriptionally induces TNFAIP2 expression through its CTAR2 domain via NF-κB; a specific NF-κB binding site was identified at −3,869 to −3,860 bp of the TNFAIP2 promoter. TNFAIP2 associates with actin (co-immunoprecipitation), participates in actin-based membrane protrusion formation, and promotes LMP1-induced cell motility. Quantitative RT-PCR, Western blot, luciferase reporter assay, NF-κB inhibition, p65 siRNA knockdown, co-immunoprecipitation, immunofluorescence microscopy, transwell migration assay Oncogene High 23975427
2015 KLF5 directly binds the TNFAIP2 gene promoter and activates its transcription; TNFAIP2 in turn interacts with the small GTPases Rac1 and Cdc42, increasing their activities to alter the actin cytoskeleton and cell morphology, thereby promoting breast cancer cell proliferation, migration, and invasion. ChIP assay, luciferase reporter assay, co-immunoprecipitation, GTPase activity assays (Rac1/Cdc42 pull-down), siRNA knockdown, cell migration/invasion assays Oncogene High 26189798
2015 TNFAIP2 inhibits NF-κB activity and downstream IL-8 production, acting as an autoinhibitor of the early TNFα response. A genetic variant (rs8126) that increases TNFAIP2 expression correlates with decreased IL-8 and worse survival in septic shock patients. In vitro microarray gene expression, NF-κB reporter assay, cytokine measurement (IL-8), genetic association study Journal of innate immunity Medium 26347487
2016 TNFAIP2 expression is induced by Legionella pneumophila infection in macrophages via NF-κB-dependent transcription (histone H4 acetylation at the TNFAIP2 promoter detected by ChIP-seq); knockdown of TNFAIP2 reduces intracellular L. pneumophila replication, indicating a pro-bacterial role. ChIP-seq (H4 acetylation), qRT-PCR, Western blot, TNFAIP2 siRNA knockdown with intracellular bacterial replication assay The Journal of infectious diseases Medium 27130431
2017 Knockdown of TNFAIP2 in esophageal squamous cell carcinoma cells decreases expression of β-catenin downstream targets (c-Myc, cyclin D1, MMP-7, Snail) and upregulates E-cadherin and p-GSK-3β, placing TNFAIP2 as a positive regulator of the Wnt/β-catenin signaling pathway. Lentivirus-mediated RNAi knockdown, Western blot, qRT-PCR, cell proliferation/migration/invasion assays Oncology reports Medium 28393234
2019 TNFAIP2 translation is controlled by upstream open reading frames (uORFs) in its transcript leader sequence that suppress cap-dependent translation in monocytes; during monocyte-to-macrophage differentiation, these uORFs are inactivated, enabling a large increase in TNFAIP2 protein expression. Reporter assays (uORF mutagenesis), Western blot, polysome profiling, monocyte differentiation model Cellular and molecular life sciences High 31392347
2019 TNFAIP2 knockdown in platinum-resistant urothelial carcinoma cells upregulates E-cadherin and downregulates TWIST1, reducing motility; TNFAIP2 overexpression has the opposite effect. Global gene expression analysis identified MTDH as a positive regulator of TNFAIP2-driven EMT. siRNA knockdown, lentiviral overexpression, microarray global gene expression analysis, Western blot, migration/invasion assays Laboratory investigation Medium 31263157
2020 Tnfaip2 acts as an inhibitor of cellular reprogramming and is required for embryonic stem cell (ESC) differentiation; Tnfaip2-deficient ESCs fail to induce triacylglycerol (TAG) synthesis and lipid droplet formation coincident with reduced vimentin expression. Epistasis analysis places Tnfaip2 upstream of vimentin in suppressing reprogramming. Palmitic acid supplementation rescues differentiation defects in Tnfaip2-null ESCs. Tnfaip2 knockout ESCs, reprogramming assays, lipidomic analysis (TAG/lipid droplets), vimentin expression analysis, genetic epistasis, palmitic acid rescue EMBO reports High 33300287
2021 STAT1 (phosphorylated) binds the enhancer loci of TNFAIP2, recruits the acetyltransferase EP300, and increases H3K27ac enrichment, thereby transcriptionally upregulating TNFAIP2 in the context of inflammatory bowel disease. ChIP-PCR, co-immunoprecipitation (STAT1–EP300 interaction), RNA-seq, EP300 inhibitor in DSS colitis mouse model Clinical epigenetics Medium 34112215
2022 TNFAIP2 is required for tunneling nanotube (TNT) formation in podocytes; in diabetic nephropathy, the TNFAIP2-TNT system allows autophagosome and lysosome exchange between podocytes, alleviating AGE-induced lysosomal dysfunction and apoptosis. Tnfaip2 deletion in mice exacerbates albuminuria, podocyte injury, and autophagic flux blockade. Tnfaip2 knockout mice (STZ-induced DN model), live-cell imaging of organelle transfer, lysosome/autophagosome functional assays, Tnfaip2 overexpression Autophagy High 35659195
2023 TNFAIP2 contains a DLG motif that directly binds the Kelch domain of KEAP1, competing with NRF2, thereby preventing NRF2 ubiquitin-proteasomal degradation. This leads to NRF2 accumulation, suppression of ROS-mediated JNK phosphorylation, and cisplatin resistance in head and neck squamous cell carcinoma. Co-immunoprecipitation coupled with mass spectrometry (Co-IP/MS), mutagenesis of DLG motif, Western blot, flow cytometry (ROS, apoptosis), xenograft and 4NQO mouse models, siRNA knockdown Journal of experimental & clinical cancer research High 37525222
2023 TNFAIP2 interacts with IQGAP1 and Integrin β4 (co-immunoprecipitation); Integrin β4 activates RAC1 through the TNFAIP2–IQGAP1 axis, conferring DNA damage-related drug resistance in triple-negative breast cancer. Co-immunoprecipitation, RAC1 activity assay, siRNA knockdown, drug resistance assays eLife High 37787041
2024 TNFAIP2 promotes angiogenesis in triple-negative breast cancer by activating a Rac1→ERK→AP-1 (c-Jun/Fra1) signaling cascade; AP-1 directly binds the HIF1α gene promoter to enhance HIF1α transcription, which drives VEGF-dependent angiogenesis. Chromatin immunoprecipitation (AP-1 binding to HIF1α promoter), luciferase reporter assay, ERK inhibitor (U0126/trametinib) treatment, VEGFR inhibitor (Apatinib), RAC1 activity assay, xenograft mouse model Cell death & disease High 39532855
2025 TNFAIP2 binds phosphatidylinositol 4,5-bisphosphate (PIP2) and promotes CSF1R aggregate/cluster formation in macrophages via PIP2, RalA, and the exocyst complex, enabling efficient CSF1R dimerization and activation in response to CSF-1. Additionally, TNFAIP2 enhances trafficking of CSF1R to the cell surface through the same PIP2–RalA–exocyst pathway. Inhibition/knockdown of TNFAIP2, 293-cell reconstitution of CSF1R clustering, PIP2-binding motif mutagenesis, PIP2 depletion, co-immunoprecipitation, CSF1R surface trafficking assay, RalA and exocyst complex functional experiments Life science alliance / Journal of leukocyte biology High 39939179 41158107
2025 TGF-β induces acetylation of KLF5, and acetylated KLF5 directly binds the TNFAIP2 promoter to drive TNFAIP2 transcription and EMT in nasopharyngeal carcinoma; the pro-invasive effects of acetylated KLF5 depend on TNFAIP2. KLF5 acetylation analysis, ChIP assay (KLF5 binding to TNFAIP2 promoter), TNFAIP2 rescue experiments, in vivo NPC mouse model with TGF-β treatment Experimental cell research Medium 40054652
2025 TNFAIP2 interacts with KEAP1 and prevents IKKβ ubiquitination at K63, protecting IKKβ from proteasomal degradation and sustaining NF-κB signaling to facilitate EMT and lymphangiogenesis in oral squamous cell carcinoma. Co-immunoprecipitation, conditional Tnfaip2 knockout mouse (4NQO-induced OSCC model), Western blot (ubiquitination), gene set enrichment analysis, siRNA delivery in vivo Cell communication and signaling Medium 39948570

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. Oncogene 128 26189798
2018 The roles of TNFAIP2 in cancers and infectious diseases. Journal of cellular and molecular medicine 79 30145807
2022 Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. Autophagy 78 35659195
2015 MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. Journal of experimental & clinical cancer research : CR 68 25888093
2000 Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer research 65 10766166
2011 A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 64 21934093
2013 NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma. Oncogene 62 23975427
1994 B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome. The Journal of biological chemistry 62 8106408
2010 A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 50 21057457
2023 TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling. Journal of experimental & clinical cancer research : CR 36 37525222
2017 Downregulation of TNFAIP2 suppresses proliferation and metastasis in esophageal squamous cell carcinoma through activation of the Wnt/β-catenin signaling pathway. Oncology reports 34 28393234
2013 The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PloS one 32 23724109
2021 STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel disease. Clinical epigenetics 31 34112215
2018 miR-221 alleviates the inflammatory response and cell apoptosis of neuronal cell through targeting TNFAIP2 in spinal cord ischemia-reperfusion. Neuroreport 31 29596155
2023 Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1. eLife 24 37787041
2020 TNFAIP2 Promotes Non-Small Cell Lung Cancer Cells and Targeted by miR-145-5p. DNA and cell biology 23 32456459
2015 TNFAIP2 Inhibits Early TNFα-Induced NF-x03BA;B Signaling and Decreases Survival in Septic Shock Patients. Journal of innate immunity 22 26347487
2019 TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory investigation; a journal of technical methods and pathology 21 31263157
2011 Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. The American journal of surgical pathology 20 21921781
2002 Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clinical cancer research : an official journal of the American Association for Cancer Research 19 11839676
2014 A functional TNFAIP2 3'-UTR rs8126 genetic polymorphism contributes to risk of esophageal squamous cell carcinoma. PloS one 18 25383966
2020 Tnfaip2/exoc3-driven lipid metabolism is essential for stem cell differentiation and organ homeostasis. EMBO reports 17 33300287
2022 Tnfaip2 promotes atherogenesis by enhancing oxidative stress induced inflammation. Molecular immunology 16 36084515
2016 Genome-wide Chromatin Profiling of Legionella pneumophila-Infected Human Macrophages Reveals Activation of the Probacterial Host Factor TNFAIP2. The Journal of infectious diseases 13 27130431
2021 Functional miR-142a-3p Induces Apoptosis and Macrophage Polarization by Targeting tnfaip2 and glut3 in Grass Carp (Ctenopharyngodon idella). Frontiers in immunology 12 34262558
2024 TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. Cell death & disease 11 39532855
2019 Translation of TNFAIP2 is tightly controlled by upstream open reading frames. Cellular and molecular life sciences : CMLS 10 31392347
2025 TNFAIP2 promotes NF-κB signaling mediate lymph node metastasis of oral squamous cell carcinoma by protecting IKKβ from ubiquitin proteasome degradation. Cell communication and signaling : CCS 8 39948570
2025 Identification of TNFAIP2 as a unique cellular regulator of CSF-1 receptor activation. Life science alliance 7 39939179
2024 TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms. Pharmacological research 5 38688431
2023 Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy. Journal of neuro-oncology 5 37819535
2020 Genetic polymorphisms of PGF and TNFAIP2 genes related to cervical cancer risk among Uygur females from China. BMC medical genetics 5 33109108
2025 Acrylamide-induced noradrenergic axon degeneration is promoted via a non-cell autonomous mechanism, involving microglial Tnfaip2/TNF-α and oxidative stress pathways. Journal of hazardous materials 3 40664071
2025 TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma. Scientific reports 2 40664878
2024 The miR-146b-3p/TNFAIP2 axis regulates cell differentiation in acute myeloid leukaemia. Aging 1 38271140
2022 Susceptibility of TNFAIP8, TNFAIP8L1, and TNFAIP2 Gene Polymorphisms on Cancer Risk: A Comprehensive Review and Meta-Analysis of Case-Control Studies. Technology in cancer research & treatment 1 36254562
2026 Human umbilical cord mesenchymal stem cell delivery of mitochondria to melanocytes enhances skin repigmentation efficacy in autologous epidermal cell suspension transplantation through the TNFAIP2-TNT system. International journal of biological sciences 0 41694594
2025 TGF-β-induced acetylation of KLF5 drives TNFAIP2 transcription and EMT in nasopharyngeal carcinoma: Unveiling a novel regulatory mechanism. Experimental cell research 0 40054652
2025 Targeting TNFAIP2 with NIR-II CRISPR-Cas9 nanosystem to overcome cisplatin resistance in laryngeal cancer. NPJ precision oncology 0 40731142
2025 TNFAIP2 increases macrophage response to CSF-1 through multiple effects on CSF-1 receptor. Journal of leukocyte biology 0 41158107